New cord blood treatment could transform transplants for bone marrow diseases

NCT ID NCT03173937

Recruiting now Disease control Sponsor: National Heart, Lung, and Blood Institute (NHLBI) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 6 times

Summary

This study tests whether a new cord blood stem cell product, Omidubicel, can improve transplant outcomes for people with severe aplastic anemia or a related bone marrow disorder. Participants receive a combination of stem cells from a family member and specially processed cord blood from an unrelated donor. The goal is to help the new cells grow faster and reduce complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Omidubicel (expanded cord blood stem cells)
What this could lead to: If successful, this could provide a safer and more effective transplant option for people with severe aplastic anemia or MDS who lack a matched bone marrow donor.
What could go wrong: This is an early-phase trial with only 37 participants, so results may not apply to everyone. There are risks from chemotherapy, radiation, and graft-versus-host disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPO-PLASTIC MDS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired aplastic anemia aplastic anemia myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPO-PLASTIC MDS MYELODYSPLASTIC SYNDROME (MDS) SEVERE APLASTIC ANEMIA

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.